Back to Search
Start Over
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study
- Source :
- Clinical and Experimental Medicine. 19:357-366
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud's phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients' life. The management of vascular disease can be challenging for the clinician because of the suboptimal tolerability of the treatments and lack of consensus on the best therapeutic approach. Intravenous iloprost, a synthetic analogue of prostacyclin, is broadly used for the treatment of RP and ischemic ulcers secondary to SSc. However, no standardized protocol on iloprost use is currently available and, consequently, the management of this treatment is largely based on the experience of each single center. The PROSIT project is an observational, multicenter study aiming to investigate the current treatments for SSc vasculopathy, the use of prostanoids, with special regard to iloprost, and the perception of the treatment from a patient's perspective. The study was conducted on a cohort of 346 patients from eight Italian centers and included a structured survey addressed to physicians, data collected from patient's medical records and two patient-administered questionnaires assessing the level of satisfaction, tolerability and perception of the efficacy of Iloprost. PROSIT data confirmed that in the contest of SSc iloprost represents the first-line choice for the management of severe RP and DU. Moreover, it is a well-tolerated treatment as reported by patients' experience. Although a standard protocol for the treatment of SSc-related vasculopathy is lacking, PROSIT study identified different therapeutic approaches largely supported by tertiary Italian centers. Further studies are needed in order to optimize the best treatment for SSc vascular diseases, in particular to improve the best iloprost schedule management.
- Subjects :
- Male
0301 basic medicine
Settore MED/16 - REUMATOLOGIA
Raynaud’s phenomenon
Vasodilator Agents
Vasculopathy
Scleroderma
Tertiary Care Centers
0302 clinical medicine
80 and over
PROSIT
Disease management (health)
Digital ulcers, Iloprost, PROSIT, Raynaud’s phenomenon, Systemic sclerosis, Vasculopathy
Aged, 80 and over
Peripheral Vascular Diseases
Medical record
Disease Management
Digital ulcers
General Medicine
Middle Aged
Treatment Outcome
Italy
Tolerability
030220 oncology & carcinogenesis
Cohort
Systemic sclerosis
Female
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Referral
General Biochemistry, Genetics and Molecular Biology
Young Adult
03 medical and health sciences
medicine
Humans
Iloprost
Aged
Retrospective Studies
Scleroderma, Systemic
Intensive care medicine
business.industry
Systemic
Retrospective cohort study
030104 developmental biology
Observational study
business
Subjects
Details
- ISSN :
- 15919528 and 15918890
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Clinical and Experimental Medicine
- Accession number :
- edsair.doi.dedup.....542d0057846e85f12af029264193eae5